INTRODUCTION {#s1}
============

Epilepsy is the most common central nervous system (CNS) disease in childhood, with an incidence of 70.1 per 100,000 children younger than 2 yr of age ([@MCS002949QIAC4]). Severe epilepsies of infancy are devastating disorders associated with developmental delay (DD). Recent studies of early-onset epileptic encephalopathies using next-generation sequencing have revealed several new disease genes, many harboring de novo mutations with autosomal dominant inheritance, such as *GABRB3*, *ALG13*, *KCNB1*, *CHD2*, *DNM1*, *GNAO1*, *GRIN2A*, and *GRIN2B* ([@MCS002949QIAC5]; [@MCS002949QIAC15]; [@MCS002949QIAC6]; [@MCS002949QIAC11]). Myers et al. studied 4760 trio families with neurodevelopmental disease in the probands and detected five individuals with de novo *PPP3CA* mutations ([@MCS002949QIAC13]). Another de novo mutation in *PPP3CA* was identified in an individual with severe undiagnosed developmental disorder by exome sequencing of 4293 families ([@MCS002949QIAC3]). In addition, Mizuguchi et al. reported de novo mutations of the *PPP3CA* gene associated with epileptic encephalopathies ([@MCS002949QIAC12]).

The *PPP3CA* gene encodes the protein phosphatase 3 catalytic subunit α (PPP3CA: MIM 114105), which forms part of the Ca^2+^-interacting serine/threonine protein phosphatase calcineurin (CN). CN couples intracellular Ca^2+^ signals to various cellular responses, such as T-cell activation, vesicular trafficking, cell growth, and apoptosis. Although widely distributed, CN exhibits particularly high expression in the brain and in lymphocytes. The zebrafish *Ppp3ca* gene is expressed in the cerebellum, hindbrain, tectum olfactory epithelium, and skin as early as 72 h postfertilization. Further, the spatial and temporal expression patterns of the five CN genes generally detected in the CNS---three encoding catalytic subunits (*PPP3CA--C*) and two encoding regulatory subunits (*PPP3R1* and *PPP3R2*)---also implicate CN in neuronal development ([@MCS002949QIAC7]). Indeed, *Ppp3ca*^−/−^ mice show defects in CNS development as well as reduced bone mineral density ([@MCS002949QIAC8]; [@MCS002949QIAC16]).

Proper neural circuit development is essential for both cognitive function and maintaining excitatory--inhibitory balance, which is disrupted in epilepsy. Thus, it is not surprising that various de novo mutations in CN subunit genes are associated with early-onset epilepsy accompanied by neurodevelopment delay. In this study, we identified a novel de novo frameshift mutation of *PPP3CA* in an infant female with early-onset refractory epilepsy. We also review previous cases with de novo *PPP3CA* mutations.

RESULTS {#s2}
=======

Clinical Presentation and Family History {#s2a}
----------------------------------------

The female case patient was first diagnosed with seizures at 2 mo of age, and at presentation was experiencing seizures roughly 10 times per day without fever. Routine blood cell and biochemical examinations were normal. However, head magnetic resonance imaging (MRI) revealed dilation of lateral ventricles. Sleep electroencephalograph (EEG) showed multiple spike waves, spike, sharp-slow, and spike-slow waves on left central and posterior temporal lobes with hemispheric asymmetry, under the background activity of 4--5 Hz θ wave and low-to-moderate 2--3 Hz δ waves. She was treated by levetiracetam 0.5 ml q12h, but seizures persisted, presenting as sudden blinks, upper limb inflections, and periodic leg shaking in clusters of one to 20 times, with clusters occurring five to 20 times per day. Levetiracetam was increased to 1.75 ml q12h, and combined with sodium valproate, and valproic acid SR tablets 1--2.5 ml q12h, and topiramate tablets 3.125--25 mg gradually, but epileptic seizures still occurred. She was then treated with a ketogenic diet. On admission, abnormalities in head MRI were observed, including brain dysplasia with cystic right basal ganglia, thin corpus callosum, and widened brain interval ([Fig. 1](#MCS002949QIAF1){ref-type="fig"}A--D). Hippocampal MRI also revealed a relatively small hippocampus. The X-ray images showed low bone density in the left hand and slightly elevated bone density of the metaphysis at the distal end of the ulnar radius. Head magnetic resonance spectroscopy (MRS) showed reduced peak *N*-acetylaspartate (NAA) in the bilateral basal ganglia and thalamus, indicating neuronal lesions. The ketogenic diet was added to 180 ml q6h, with antiepileptic drug treatment because of intractable seizures. She was able to maintain normal blood glucose/ketone during the ketogenic diet. The patient subsequently visited at 8.5, 9.5, and 11.5 mo old, but epileptic seizures remained and developmental quotient (DQ) was \<20. The patient was diagnosed with intractable epilepsy and DD. As of the last follow-up by phone at 16 mo old, the patient still could not raise her head and exhibited frequent seizures (epilepsy every 15 min) under drug control ([Fig. 2](#MCS002949QIAF2){ref-type="fig"}). There was no similar medical history in her family.

![Brain magnetic resonance images of the case patient. (*A*) Sagittal T1 FLAIR image showing brain hypoplasia and thin corpus callosum. (*B*) Axial diffusion-weighted image showing cystic basal ganglia. (*C*) Coronal fast spin echo T2 image. (*D*) Axial T2 FLAIR image showing brain interval enlargement.](MCS002949Qia_F1){#MCS002949QIAF1}

![Clinical summary of the case patient. Age at visits is shown by the thick green axis with arrows. The clinical features are described in yellow blocks. Clinical examination results are summarized in the pink blocks at the corresponding age. Clinical treatment is summarized in the sky blue blocks.](MCS002949Qia_F2){#MCS002949QIAF2}

Genomic Analysis {#s2b}
----------------

The mean depth of the sequencing data in this family was ∼120× ([Supplemental Table S1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a002949/-/DC1)). We identified a novel frameshift mutation (c.1255_1256del, p.Ser419Cysfs\*31) in *PPP3CA* ([Fig. 3](#MCS002949QIAF3){ref-type="fig"}A). The mutation predicted a truncated protein with a 30-amino acid addition from position 419 ([Fig. 3](#MCS002949QIAF3){ref-type="fig"}B,C). The mutation was not detected in her parents; therefore, it was classified as a de novo mutation ([Table 1](#MCS002949QIATB1){ref-type="table"}). The affected region is located near the calmodulin-binding domain and is conserved among species, including human, chimp, rat, mouse, dog, frog, and zebrafish ([Fig. 3](#MCS002949QIAF3){ref-type="fig"}C). The sequence change predicts loss of the autoinhibitory (AI) domain ([Fig. 4](#MCS002949QIAF4){ref-type="fig"}). The mutation was not reported in the 1000 Genome Project (1KG), Exome Aggregation Consortium (ExAC), Human Genome Mutation Database (HGMD), or PubMed and is not recorded in our laboratory internal database of 15,000 pediatric patients, including 2000 epilepsy patients.

![Rare de novo frameshift mutation in *PPP3CA*. (*A*) The trio family and the de novo frameshift mutation detected by whole-exome sequencing and confirmed by Sanger sequencing. (*B*) The predicted structure of *PPP3CA*. The structure of wild-type *PPP3CA* is shown in green, and the predicted structure of the mutant is shown in purple. The frameshift mutation encodes a truncated 449-amino acid protein. (*C*) The mutation region is conserved among human, chimp, rat, mouse, dog, frog, zebrafish, fruit fly, and *Caenorhabditis elegans*.](MCS002949Qia_F3){#MCS002949QIAF3}

![The previously reported mutations of *PPP3CA*. Boxes in gray/white with numbers are the exons. The dark blue frames demarcate the catalytic, calcineurin B-binding (CnBB), calmodulin-binding (CaMB), and autoinhibitory (AI) domains. The mutations indicated by black arrows were reported in previous papers, and that indicated by the red arrow was detected in the present study.](MCS002949Qia_F4){#MCS002949QIAF4}

###### 

*PPP3CA* variant in this study

  Gene       Chr: position GRCh 37(hg19)   HGVS                                                       Variant type   Effect^a^    Genotype       Origin    Clinvar ID
  ---------- ----------------------------- ---------------------------------------------------------- -------------- ------------ -------------- --------- --------------
  *PPP3CA*   Chr 4:101953506               NM_000944:c.1255_1256delAG NP_000935.1:p.Ser419Cysfs\*31   Deletion       Pathogenic   Heterozygous   De novo   SCV000692475

HGVS, Human Genome Variation Society.

^a^Evaluated according to ACMG guidelines.

DISCUSSION {#s3}
==========

The calcium-dependent CN is an important regulator of synaptic vesicle recycling, a critical process controlling neurotransmission ([@MCS002949QIAC1]). The *PPP3CA* gene encodes one isoform of the catalytic subunit (calcineurin A), which forms a functional isodimer with the regulatory subunit (calcineurin B).

Recent studies have identified de novo mutations of *PPP3CA* associated with epileptic encephalopathies ([@MCS002949QIAC13]; [@MCS002949QIAC12]). Including this study, a total of 12 *PPP3CA* mutations have been documented in 14 patients (Cases 2 and 3 share the same mutation as do Cases 9 and 10) ([Table 2](#MCS002949QIATB2){ref-type="table"}). The three deleterious mutations in Case 1, 2, and 11, including two frameshift mutations (c.1255_1256delAG and c.1290dupC) and one nonsense mutation (c.1333C \> T, p.Gln445Ter), may delete the AI domain, which in turn would alter CN activity. These three patients all presented with early-onset refractory seizures and severe DD.

###### 

Genotype and clinical features of 14 patients with *PPP3CA* mutations, including the current case patient (case 1)

  Case number (PMID)                        Case 1 (this study)                                                                                                          Case 2 (29432562)                                             Case 3 (28942967)                     Case 4 (29432562)                                     Case 5 (29432562)                                        Case 6 (29432562)                                             Case 7 (28135719)
  ----------------------------------------- ---------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------- ------------------------------------- ----------------------------------------------------- -------------------------------------------------------- ------------------------------------------------------------- -------------------------
  Age/gender                                11.5 m/F                                                                                                                     2 y/F                                                         12.5 y/M                              4 y/F                                                 19 y/F                                                   2 y/M                                                         NA/F
  Variant (NM_000944.4)                     c.1255_1256del p.Ser419Cysfs\*31                                                                                             c.1290dupC p.Met431Hisfs\*20                                  c.275A \> G p.His92Arg                c.275A \> G p.His92Arg                                c.449A \> T p.Asn150Ile                                  c.702C \> G p.Asp234Glu                                       c.760A \> G p.Arg254Gly
  Variant type                              Frameshift                                                                                                                   Frameshift                                                    Missense                              Missense                                              Missense                                                 Missense                                                      Missense
  Domain                                    /                                                                                                                            /                                                             Catalytic                             Catalytic                                             Catalytic                                                Catalytic                                                     Catalytic
  Inheritance                               De novo                                                                                                                      De novo                                                       De novo                               De novo                                               Not maternal                                             De novo                                                       De novo
  Seizure onset                             2 m                                                                                                                          6 m                                                           3 m                                   22 m                                                  8 m                                                      7 m                                                           NA
  EEG                                       Sharp, spike, sharp-slow, spike-slow wave                                                                                    Hypsarrhythmia, repetitive polyspike-slow waves               Bilateral occipital spikes; MFD, PS   Occipital polyspike-slow waves                        Hypsarrhythmia, spike-slow waves, polyspike-slow waves   Hypsarrhythmia, multifocal epileptic discharge                NA
  DD (onset)                                7.5 m                                                                                                                        NA                                                            3 m                                   16 m                                                  5 m                                                      6 m                                                           NA
  MRI: ventricle/white matter/hippocampal   Dilation/N/Might be small                                                                                                    NA/NA/NA                                                      N/N/N                                 Normal at 4 y                                         Normal at 8 y                                            NA/NA/NA                                                      NA/NA/NA
  MRS                                       Basal ganglia and hypothalamic NAA peak decrease, neuronal lesion                                                            NA                                                            NA                                    NA                                                    NA                                                       NA                                                            NA
  Skeletal                                  Low bone density in the left hand, and the density of the metaphysis at the distal end of the ulnar radius raised slightly   N                                                             NA                                    N                                                     N                                                        N                                                             NA
  Treatment                                 Refractory; some response: KD; no response: LEV, VPA, TPM                                                                    Refractory; partial response: VPA; no response: TPM, et al.   Refractory; partial response: LEV     Refractory; no response: VPA; partial response: LTG   Refractory; no response: VPA, et al.                     Refractory; partial response: VPA; no response: TPM, et al.   NA

  Case number (PMID)                        Case 8 (28942967)                                                   Case 9 (28942967)                                     Case 10 (28942967)         Case 11 (28942967)                                                Case 12 (28942967)                  Case 13 (29432562)                         Case 14 (29432562)
  ----------------------------------------- ------------------------------------------------------------------- ----------------------------------------------------- -------------------------- ----------------------------------------------------------------- ----------------------------------- ------------------------------------------ -------------------------------------------------
  Age/gender                                10 y/F                                                              22 y/F                                                5.5 y/F                    7 y/M                                                             21.5 y/F                            5 y/F                                      7 y/M
  Variant (NM_000944.4)                     c.843C \> G p.His281Gln                                             c.844G \> A p.Glu282Lys                               c.844G \> A p.Glu282Lys    c.1333C \> T p.Gln445Ter                                          c.1339G \> A p.Ala447Thr            c.1408T \> C p.Phe470Leu                   c.1417G \> A p.Ala473Thr
  Variant type                              Missense                                                            Missense                                              Missense                   Nonsense                                                          Missense                            Missense                                   Missense
  Domain                                    Catalytic                                                           Catalytic                                             Catalytic                  /                                                                 /                                   AI                                         AI
  Inheritance                               De novo                                                             De novo                                               De novo                    De novo                                                           De novo                             De novo                                    De novo
  Seizure onset                             3 m                                                                 4 y                                                   NA                         6 w                                                               3.5 y                               /                                          9 m
  EEG                                       MFD; frontal sharp and spikes                                       GSW, PS and wave, abnormal background                 MFD, abnormal background   Hypsarrhythmia; MFD, GSW                                          MFD                                 /                                          Abnormal background without epileptic discharge
  DD/ID (onset)                             3 m                                                                 2 y                                                   Birth                      1 m                                                               2 y                                 At birth                                   10 m
  MRI: ventricle/white matter/hippocampal   NA/NA/NA                                                            NA/NA/NA                                              N/N/N                      NA/Loss/NA                                                        N/N/N                               NA/NA/NA                                   Enlargement/change/NA
  MRS                                       NA                                                                  NA                                                    NA                         Low NAA to choline ratio                                          NA                                  NA                                         NA
  Skeletal                                  NA                                                                  NA                                                    NA                         NA                                                                NA                                  Gracile bones, fractures, arthrogryposis   Arthrogryposis
  Treatment                                 ES responsive: steroids, VGB; focal epilepsy refractory: VPA, TPM   Refractory during childhood; seizure-free: VPA, LTG   NA                         Refractory; some response: KD, et al.; no response: LEV, et al.   Refractory; partial response: VNS   NA                                         Tractable; response: LTG

AI, auto-inhibitory; DD, developmental delay; EEG, electroencephalogram; ES, epileptic spasms; ExAC, exome aggregation consortium; GSW, generalized spike and slow wave; KD, ketogenic diet; LEV, levetiracetam; LTG, lamotrigine; m, month; MRI, magnetic resonance imaging; MFD, multifocal epileptiform discharges; MRS, magnetic resonance spectroscopy; NAA, N-acetylaspartate; N, normal; NA, not mentioned; PS, polyspikes; TPM, topiramate; VGB, vigabatrin; VPA, valproate; w, week; m, month; y, year; 1KG, 1000 genome; /, not in any domain.

The pLI value of *PPP3CA* is 1, indicating extreme loss-of-function (LoF) intolerance, possibly due to nonsense-mediated mRNA decay (NMD) and ensuing haploinsufficiency. However, Mizuguchi et al. reported that one frameshift mutation (c.1290dupC) escaped NMD ([@MCS002949QIAC12]). In our study, we found that in 293 cells transfected with a plasmid encoding the c.1255_1256del mutant of *PPP3CA*, the mRNA expression levels were similar to the wild type, but the mutant protein cannot be detected by western blot, even after repeated experiments ([Supplemental Fig. S1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a002949/-/DC1)). Thus, we speculated that the frameshift mutation (p.Ser419Cysfs\*31) confers haploinsufficiency because of an unstable protein. In contrast, two missense mutations (p.Phe470Leu and p.Ala473Thr) located in the AI domain were classified as gain of function as enzyme activity was maintained ([@MCS002949QIAC12]). Both of these patients (Cases 13 and 14) showed severe skeletal abnormalities and moderate/severe DD, and Case 14 also exhibited tractable seizures. In the current case, low bone density of the left hand and slightly raised density in the metaphysis at the distal end of the ulnar radius were revealed by X-ray imaging. This suggests that the *PPP3CA* gene may also disrupt normal bone metabolism when the enzyme active is affected. In addition, MRI revealed a relatively small hippocampus, a phenotype also observed in *Ppp3ca*^−/−^ mice ([@MCS002949QIAC8]).

The catalytic domain is well conserved across species, so substitutions in this region may be deleterious. Mizuguchi et al. reported that four missense mutations identified in this domain, p.His92Arg (Cases 3 and 4), p.Asn150Ile (Case 5), p.Asp234Glu (Case 6), and p.His281Gln (Case 8), were LoF ([@MCS002949QIAC12]). These patients were diagnosed with West syndrome or Lennox--Gastaut syndrome, and all suffered from refractory seizures and profound/severe intellectual disability (ID) ([@MCS002949QIAC13]; [@MCS002949QIAC12]). However, Mizuguchi et al. found that another missense mutation in this domain, p.Glu282Lys, did not affect CN signaling in a yeast assay ([@MCS002949QIAC12]). Two patients (Cases 9 and 10) with the mutation p.Glu282Lys did not present with refractory seizures. Rather, Case 9 had mild epilepsy from age 4 to 9 yr that resolved by age 16, whereas Case 10 had no epilepsy until age 5.5 yr, although EEG showed abnormal background activity with multifocal epileptiform discharges. However, both cases suffered from severe ID. The patient with the p.Arg254Gly mutation (Case 7) reported in the Deciphering Developmental Disorders study ([@MCS002949QIAC3]) was described with an "abnormality of the nervous system," but there was no mention of epileptic seizures. This mutation has not been subjected to functional study. The missense mutation p.Ala447Thr in Case 12 is outside the functional domain, but nonetheless was associated with refractory seizures and profound ID.

In summary, all 14 patients with de novo *PPP3CA* mutations documented to date have presented with obvious DD and ID regardless of the domain mutated. Therefore, rare mutations in the catalytic domain and other domains are associated with clinically severe DD and ID. In this study, we describe a novel frameshift mutation of *PPP3CA* related to early-onset severe neurodevelopmental disease with seizures. This description further expands our knowledge of the relationships among *PPP3CA* mutations and neural deficits.

METHODS {#s4}
=======

Whole-Exome Sequencing {#s4a}
----------------------

Genomic DNA was extracted from whole blood using the QIAamp DNA Blood Mini Kit (Catalog no. 51106). Whole-exome capture was performed using the Agilent SureSelect Human All Exon 50Mb Kit followed by sequencing as 150-bp paired-end runs on an Illumina XTen platform. More than 10 GB of raw data was generated for each sample. Variants were called using the Genome Analysis Toolkit Best Practices Pipeline (Version 3.2.2) ([@MCS002949QIAC17]), and data filtering, variants prediction, and interpretation followed ACMG guidelines and our previous work ([@MCS002949QIAC14]; [@MCS002949QIAC2]). Segregation of the *PPP3CA* mutation within the family was confirmed by Sanger sequencing on the ABI 3730 Genetic Analyzer (Applied Biosystems).

Protein Structure Analysis {#s4b}
--------------------------

The secondary structures of PPP3CA in wild type and mutants were analyzed by UniProt (<http://www.uniprot.org/>), Mutalyzer (<https://www.mutalyzer.nl/>), and SWISS-MODEL (<https://www.swissmodel.expasy.org>). We downloaded the FASTA sequence of PPP3CA from UniProt (ID: Q08209) and selected 4orb.1.A as the protein structure template ([@MCS002949QIAC9]). We used MODELLER automated modeling ([@MCS002949QIAC10]). Protein structures were visualized by PyMOL 1.7.4.

ADDITIONAL INFORMATION {#s5}
======================

Data Deposition and Access {#s5a}
--------------------------

The pathogenic *PPP3CA* mutation has been submitted to ClinVar (<https://www.ncbi.nlm.nih.gov/clinvar/>) with submission number SCV000692475. Patient family permission to deposit the trio-family whole-exome sequencing data was not obtained.
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